Program
divozilimab
Also written as “Divozilimab”.
Its studies are mostly in Scleroderma, Systemic · Multiple Sclerosis · Neuromyelitis Optica, led by Biocad.
Furthest: phase 3, since Feb 3, 20234 company-led studies, 3 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biocad | 43 open or running | phase 3since Feb 3, 2023 | Feb 3, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2023First studies: 2 phase 3 studiesFirst studyNCT05726630, NCT05730699
- May 16, 2025Phase 3 study in Multiple SclerosisNCT06987851 · 44 enrolled · Russian Federation
- Aug 8, 2025Phase 1 study in Systemic Lupus ErthematosusNCT07136389 · 135 planned · Russia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07136389Systemic Lupus Erthematosus · Russia | 1 | Recruiting | Jan 1, 2026 | 135 |
| NCT06987851Multiple Sclerosis · Russian Federation | 3 | Completed | May 16, 2024 | 44 |
| NCT05730699Neuromyelitis Optica · Russian Federation | 3 | Active, not recruiting | Jan 2025 | 105 |
| NCT05726630Scleroderma, Systemic · Russia | 3 | Active, not recruiting | Oct 1, 2024 | 152 |
How it is read
Names in the registry
- “Divozilimab”, 3 entries
- “divozilimab”, 1 entry
Conditions, from the studies’ own filings
- Scleroderma, Systemic, 1 study
- Multiple Sclerosis, 1 study
- Neuromyelitis Optica, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.